Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on PK/PD and Safety of CKD-519 in Healthy Volunteers
NCT02484482Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rocacetrapib in dyslipidemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at 168 hours, Area Under the Plasma Drug Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 168 hours and 5 more. Started Jun 2015; status: completed.
02
Drugs
rocacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02484482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484482.